Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mrna expression in glioblastoma multiforme

Molecules

Volumn 15, Issue 7, 2010, Pages 4670-4678

  Karpel Massler, Georg ^a   Wirtz, Christian Rainer ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

EGFRvIII; Retrovirus mediated DNA transfer; Ribozymes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; RIBOZYME;

DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENE DELETION; GENETICS; GLIOBLASTOMA; HUMAN; METHODOLOGY; REVIEW;

DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, CATALYTIC; RNA, MESSENGER; SEQUENCE DELETION;

EID: 77955003681     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15074670     Document Type: Review

References (25)

1. Haley, J.; Whittle, N.; Bennet, P.; Kinchington, D.; Ullrich, A.; Waterfield, M. The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res. 1987, 1, 375-396.
2. Frederick, L.; Wang, X.Y.; Eley, G.; James, C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60, 1383-1387.
3. Wong, A.J.; Ruppert, J.M.; Bigner, S.H.; Grzeschik, C.H.; Humphrey, P.A.; Bigner, D.S.; Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89, 2965-2969.
4. Yamazaki, H.; Ohba, Y.; Tamaoki, N.; Shibuya, M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. 1990, 81, 773-779.
5. Sugawa, N.; Ekstrand, A.J.; James, C.D.; Collins, V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87, 8602-8606.
6. Nagane, M.; Coufal, F.; Lin, H.; Bögler, O.; Cavenee, W.K.; Huang, H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56, 5079-5086.
7. Nishikawa, R.; Ji, X.D.; Harmon, R.C.; Lazar, C.S.; Gill, G.N.; Cavenee, W.K.; Huang, H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 1994, 91, 7727-7731.
8. Karpel-Massler, G.; Schmidt, U.; Unterberg, A.; Halatsch, M.E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: Where do we stand? Mol. Cancer Res. 2009, 7, 1000-1012.
9. Halatsch, M.E.; Schmidt, U.; Bötefur, I.C.; Holland, J.F.; Ohnuma, T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J. Neurosurg. 2000, 92, 297-305.
10. Yamazaki, H.; Kijima, H.; Ohnishi, Y.; Abe, Y.; Oshika, Y.; Tsuchida, T.; Tokunaga, T.; Tsugu, A.; Ueyama, Y.; Tamaoki, N.; Nakamura, M. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 1998, 90, 581-587.
11. Haseloff, J.; Gerlach, W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988, 334, 585-591.
12. Doudna, J.A.; Cech, T.R. The chemical repertoire of natural ribozymes. Nature 2002, 418, 222-228.
13. Reymond, C.; Beaudoin, J.D.; Perreault, J.P. Modulating RNA structure and catalysis: Lessons from small cleaving ribozymes. Cell Mol. Life Sci. 2009, 66, 3937-3950.
14. Hutchins, C.J.; Rathjen, P.D.; Forster, A.C.; Symons, R.H. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 1986, 14, 3627-3640.
15. Chowrira, B.M.; Berzal-Herranz, A. and Burke, J.M. Ionic requirements for RNA binding, cleavage, and ligation by the hairpin ribozyme. Biochemistry 1993, 32, 1088-1095.
16. DeYoung, M.; Siwkowski, A.M.; Lian, Y.; Hampel, A. Catalytic properties of hairpin ribozymes derived from chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry 1995, 34, 15785-15791.
17. Hantzopoulos, P.A.; Sullenger, B.A.; Ungers, G.; Gilboa, E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. Natl. Acad. Sci. USA 1989, 86, 3519-3523.
18. Sullenger, B.A.; Lee, T.C.; Smith, C.A.; Ungers, G.E.; Gilboa, E. Expression of chimeric tRNAdriven antisense transcripts renders NIH 3T3 cells highly resistant to moloney murine leukemia virus replication. Mol. Cell Biol. 1990, 10, 6512-6523.
19. Thompson, J.D.; Ayers, D.F.; Malmstrom, T.A.; McKenzie, T.L.; Ganousis, L.; Chowrira, B.M.; Couture, L.; Stinchcomb, D.T. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res. 1995, 23, 2259-2268.
20. Long, D.M.; Uhlenbeck, O.C. Self-cleaving catalytic RNA. FASEB J. 1993, 7, 25-30.
21. Cotten, M.; Birnstiel, M.L. Ribozyme-mediated destruction of RNA in vivo. EMBO J. 1989, 8, 3861-3866.
22. Yuyama, N.; Ohkawa, J.; Inokuchi, Y.; Shirai, M.; Sato, A.; Nishikawa, S.; Taira, K. Construction of a tRNA-embedded-ribozyme trimming plasmid. Biochem. Biophys. Res. Commun. 1992, 186, 1271-1279.
23. Culver, K.W.; Van Gilder, J.; Link, C.J.; Carlstrom, T.; Buroker, T.; Yuh, W.; Koch, K.; Schabold, K.; Doornbas, S.; Wetjen, B. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 1994, 5, 343-379.
24. Luo, X.; Gong, X.; Tang, C.K. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int. J. Cancer 2003, 104, 716-721.
25. van den Bent, M.; Brandes, A.; Rampling, R.; Kouwenhoven, M.; Kros, J.; Carpentier, A.; Clement, P.; Klughammer, B.; Gorlia, T.; Lacombe, D. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. J. Clin. Oncol. 2007, 25, 18S; Abstr. 2005.